Tempus AI's Ambry Genetics Announces The Publication Of A Peer-Reviewed Study In Genetics In Medicine; 10-Year Study Reveals Lower Provider-Initiated Exome Reanalysis Rates Among Diverse Groups, Highlights Need For Proactive Programs Like Ambry's Patient For Life Program

Author: Benzinga Newsdesk | October 20, 2025 08:05am

Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry's Patient for Life™ program

Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical genetics to improve patient care and to support fair access to genetic services. The study presents a comprehensive analysis of 10 years of exome reanalysis data across diverse racial, ethnic, and ancestral (REA) groups.

The study compared provider-requested exome reanalysis with Ambry's proactive, laboratory-driven reanalysis program. Patients in the Hispanic and Latino, Asian, and African American and Black groups were found to have significantly lower rates of provider-initiated reanalysis—specifically 22%, 21% and 17%, respectively, compared to the White group at 25%. Reanalysis, whether provider-initiated or proactive, resulted in an increase in positive results across all groups, consistent with data published by the laboratory earlier this year. i

Posted In: TEM